Fibroscan can avoid liver biopsy in Indian patients with chronic hepatitis B

Abstract

Fibroscan accurately assessed fibrosis and could avoid liver biopsy in more than two-thirds of patients with CHB.

Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test

“…The full texts of 165 potentially eligible reports were obtained for further assessment. Of those, 19 papers were included in the review following full-text screening [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41].…”

“…TE is a noninvasive method gaining increasing acceptance in clinical practice. This method may reduce the need for liver biopsy and help to monitor the efficacy of treatment [23].…”

Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B

“…Transient elastography (TE, Fibroscan; Echosens, Paris, France) is a new non‐invasive diagnostic test developed in the last decade to assess liver stiffness . Many studies have evaluated the diagnostic accuracy of this technology . While several meta‐analyses have already been conducted in patients with chronic hepatitis C (CHC), there have been only a few meta‐analyses performed in CHB patients.…”

Increased Pygo2 expression in liver of patients with hepatitis B virus‐related fibrosis

“…The LSM of patients were as follows (KPa): G1F0, 3.0 ± 1.2; G1F1, 4.5 ± 2.2; G2F2, 8.3 ± 2.4; G3F3, 10.2 ± 5.3; G4F4, 16.1 ± 4.5 ( P < 0.05 respectively). The cutoff values were: ≥4.9 for F1, ≥5.6 for F2, ≥7.2 for F3, ≥10.8 for F4 .…”